Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver ...

New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

In these cases, the major issue is to distinguish FNH-like nodules from hepatocellular carcinoma (HCC). A mesenchymal hamartoma is another uncommon benign lesion, which is composed of bile ducts ...

Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

PRINCETON, N.J. - Bristol Myers Squibb (NYSE: BMY), a prominent pharmaceutical company with a market capitalization of nearly $120 billion and impressive gross profit margins of 76%, received a ...

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”) ...